Itraconazol Viatris

Itraconazole, the active ingredient in Itraconazol Viatris, is a triazole antifungal presented as an oral formulation for systemic use. It is employed to treat a range of superficial and systemic mycotic infections in adult patients, including aspergillosis and histoplasmosis.

GNH USA supplies Itraconazol Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance.

Itraconazol Viatris is a triazole antifungal that targets invasive and superficial fungal infections. - Aspergillosis: treatment of invasive disease to eradicate the fungal pathogen. - Blastomycosis: eradication of systemic infection and prevention of relapse. - Histoplasmosis: management of acute and chronic forms of the disease. - Coccidioidomycosis: therapy for disseminated infection. - Dermatophytosis: resolution of skin fungal infections. - Systemic mycoses: broad‑spectrum control of deep fungal infections.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes after dosing. - Abdominal pain: discomfort in the stomach region. - Headache: transient mild headache. - Rash: skin irritation or mild erythema. - Taste disturbance: altered taste perception.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Congestive heart failure: fluid retention and reduced cardiac function. - Severe allergic reactions: anaphylaxis or angioedema. - QT prolongation: cardiac rhythm disturbances. - Visual disturbances: blurred vision or photophobia. - Peripheral neuropathy: numbness or tingling in extremities.

Before initiating therapy, consider the following precautions: - Liver function monitoring: assess baseline and periodic liver enzymes. - Drug interaction review: evaluate concomitant medications for CYP3A4 interactions. - Cardiac assessment: screen for existing heart failure or edema. - Pregnancy: avoid use unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Itraconazole has a notable interaction profile that requires careful management. Major Interactions (Avoid): - Rifampin: markedly reduces itraconazole plasma levels. - Ketoconazole: may increase toxicity due to additive CYP3A4 inhibition. - Macrolide antibiotics (e.g., erythromycin): can raise itraconazole concentrations. - Strong CYP3A4 inducers (e.g., carbamazepine): diminish therapeutic effect. Moderate Interactions (Monitor Closely): - Statins (e.g., simvastatin): heightened risk of myopathy. - Warfarin: potential alteration of anticoagulant response. - Oral contraceptives: possible reduction in efficacy.